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Abstract
Background: Type 2 diabetes mellitus is associated with risk of congestive heart failure (CHF), cognitive dysfunction and
depression. CHF itself is linked both to poor cognition and depression. The ventricular N-terminal pro-brain natriuretic
peptide (NT-proBNP) is a marker of CHF, suggesting potential as a marker for cognitive impairment and/or depression. This
was tested in the Edinburgh Type 2 Diabetes Study (ET2DS).
Methodology and Principal Findings: Cross-sectional analysis of 1066 men and women aged 60–75 with type 2 diabetes.
Results from seven neuropsychological tests were combined in a standardised general cognitive ability factor, ‘g’. A
vocabulary-based test estimated pre-morbid cognitive ability. The Hospital Anxiety and Depression Scale (HADS) assessed
possible depression. After adjustment for age and sex, raised plasma NT-proBNP was weakly associated with lower ‘g’ and
higher depression scores (ß20.09, 95% CI 20.13 to 20.03, p = 0.004 and ß 0.08, 95% CI 0.04 to 0.12, p,0.001, respectively).
Comparing extreme quintiles of NT-proBNP, subjects in the highest quintile were more likely to have reduced cognitive
ability (within the lowest tertile of ‘g’) and ‘possible’ depression (HADS depression $8) (OR 1.80; 95% CI: 1.20, 2.70; p = 0.005
and OR 2.18; 95% CI: 1.28, 3.71; p = 0.004, respectively). Associations persisted when pre-morbid ability was adjusted for, but
as expected were no longer statistically significant following the adjustment for diabetes-related and vascular co-variates (b
20.02, 95% CI 20.07 to 0.03, p.0.05 for ‘g’; b 0.03, 95% CI 20.02 to 0.07, p.0.05 for depression scores).
Conclusion: Raised plasma NT-proBNP was weakly but statistically significantly associated with poorer cognitive function
and depression. The prospective phases of the ET2DS will help determine whether or not NT-proBNP can be considered a
risk marker for subsequent cognitive impairment and incident depression and whether it provides additional information
over and above traditional risk factors for these conditions.
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Introduction
People with type 2 diabetes are at around 1.5 to 2.5-fold
increased risk of developing dementia [1,2], a disorder involving
progressive cognitive, behavioural and motor deficits. Type 2
diabetes is also associated with an increased risk of age-associated
cognitive decline, short of frank dementia [3], and with depression
[4,5], a condition closely related to cognitive dysfunction. The
underlying mechanisms responsible for these links are unclear.
Co-morbidity with congestive heart failure (CHF) is also
prevalent in diabetes [6,7]; there appears to be a poorly defined
bidirectional relationship between cardiac function and glucose
metabolism. Cardiac stress initiates secretion of natriuretic
peptides from the ventricles [8], including N-terminal pro-brain
natriuretic peptide (NT-proBNP) the inactive metabolite of the
proBNP hormone. Higher circulating NT-proBNP concentrations
in populations with diabetes compared with healthy adults have
been reported [9,10].
There is some evidence in predominantly non-diabetic popu-
lations to suggest that BNP (with which circulating NT-proBNP is
highly correlated [11]) is associated with poor cognitive ability.
Raised natriuretic peptide concentrations have been related to low
performance on measures screening for poor global cognitive
functioning potentially indicative of dementia [12–14]. Raised
natriuretic peptide concentrations are also found in cognitively
impaired individuals [15,16] and may correlate with severity of
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dementia [14,17]. In the only prospective investigation to date,
proBNP predicted dementia at 5-year follow-up [18].
Evidence also indicates raised NT-proBNP in individuals with
major depressive disorder (MDD) and correlations between NT-
proBNP and number of depressive symptoms in healthy popula-
tions [19] and in those with cardiovascular disease [20–22].
Further, left ventricular dysfunction has been associated with poor
cognition [23–25] and depression [25]. However, overall evidence
is inconclusive, with several studies failing to find a statistically
significant association of NT-proBNP with depression or quality of
life [26–29], with cognitive function [30,31], or dementia [15].
Given these findings, NT-proBNP could function as a
biomarker of accelerated cognitive aging and depression in people
with type 2 diabetes. High prevalence of cognitive and mood
disorders in type 2 diabetes offers an interesting and novel
opportunity to study the relationship between natriuretic peptides,
acting as a proxy for cardiac stress, and cognitive function and
depression. The present study aims to assess the association of NT-
proBNP with level of cognitive ability, with level of ability relative
to estimated peak pre-morbid ability, and with depressive
symptoms, in a large, representative cohort of elderly patients
with the full spectrum of severity of type 2 diabetes (the Edinburgh
Type 2 Diabetes Study, ET2DS).
Methods
Study Population
Data from the cross-sectional, baseline phase of the prospective
ET2DS were analysed. Details of the recruitment and examina-
tion for the ET2DS have been reported previously [32]. In brief,
in 2006/7, 1066 community-dwelling men and women with type 2
diabetes mellitus, aged 60 to 75 years and living in the Lothian
area of Scotland, UK, were selected at random from a
comprehensive register of patients with diabetes attending primary
or secondary care in this region. Subjects underwent detailed
physical and cognitive examinations in a dedicated research clinic
by specially trained nurses using standard operating procedures.
Ethics Statement
Assessments complied with the ethical rules of the Declaration
of Helsinki. Ethical approval for the study was obtained from the
Lothian Medical Research Ethics Committee, and all participants
gave written informed consent.
Physical Examination
Participants were assessed by self-completion questionnaire and
physical examination for a range of demographic and clinical
characteristics. Diabetes-related measurements included plasma
HbA1c, fasting glucose, duration of diabetes and mode of
treatment. Vascular measurements included systolic and diastolic
brachial blood pressure, body mass index (BMI), waist-hip ratio
(WHR), % body fat, smoking status, alcohol intake, total serum
cholesterol and ankle brachial index (ABI). ABI is the ratio of
systolic blood pressure in the ankle to the systolic blood pressure in
the arm, and has been used as a measure both of peripheral
arterial disease and more generalised subclinical atherosclerosis
[33,34]. Pre-specified criteria were used to define prior myocardial
infarction (MI), angina or stroke using a combination of self-report
of a doctor diagnosis, WHO chest pain questionnaire, 12-lead
ECG and linkage to hospital discharge records, as has been
described in detail previously [35].
Cognitive and Mood Assessment
Seven neuropsychological tests measured various dimensions of
cognitive ability. The Borkowski Verbal Fluency Test (BVFT)
examined executive function. Immediate and delayed recall was
assessed in the Logical Memory subtest (LM) of the Wechsler
Memory Scale 3rd Edition (WMS-III). The Faces subtest of the
WMS-III was a measure of non-verbal memory. Mental flexibility
and visual attention were examined by the Trail-Making Test B
(TMT-B). Several subtests of the Wechsler Adult Intelligence Scale
3rd Edition (WAIS-III) were administered: Digit Symbol Coding
(DSC; speed of information processing), Letter Number Sequenc-
ing (LNS; working memory) and the Matrix Reasoning test (MR;
non-verbal reasoning). Vocabulary (‘crystallised’ intelligence) was
measured using the combined junior and senior Mill Hill
Vocabulary scale (MHVS) synonyms. As the results of vocabulary
tests show very little mean decline with ageing, they can be used to
estimate peak, prior cognitive ability [36]. When late-life cognitive
ability scores are adjusted for vocabulary-based test scores, the
residuals correlate highly with actual measures of cognitive change
over a lifetime [37]. A score of below 24 out of 30 on the Mini-
Mental-State Examination (MMSE; [38]) indicated presence of
possible dementia. Presence of depression and anxiety was assessed
on the Hospital Anxiety and Depression Scale (HADS; [39]).
Responses were made on four-point scales, with maximum scores
of 21 on each of two subscales, the HADS-A and HADS-D. In
addition to the use of the HADS-D as a continuous outcome,
‘possible cases’ of clinical depression (HADS-D $8) were
identified. Both these applications of the HADS are widely
employed in the literature [40], and the cut-point of 8 has been
shown to have high sensitivity and specificity [41]. A majority of
participants completed the entire cognitive test battery and mood
assessment (n = 1048 to 1065 for individual tests), and provided
data on all physical measures (n = 1028 to 1066). Incompleteness
was mainly due to physical difficulty rather than test refusal.
Measurement of NT-proBNP
Fasting blood samples were taken at the research clinic, and
plasma was frozen for storage. Plasma NT-proBNP concentrations
were determined using the Elecsys 2010 electrochemiluminescence
method (Roche Diagnostics, Burgess Hill, UK) calibrated using
the manufacturer’s reagents. Manufacturer’s controls were used
with limits of acceptability defined by the manufacturer. Low
control CV was 6.7% and high control CV was 4.9%.
Statistical Methods
Distribution of values was skewed for NT-proBNP, HADS-D,
and TMT-B. These variables were transformed to their natural
logarithm values.
Individuals who perform well on one cognitive test tend to
perform well on another, so that different cognitive tests load on a
single common factor, ‘g’ [42]. Principal component analysis
revealed that all seven cognitive tests (LM, Faces, MR, DSC,
TMT-B, LNS, BVFT) could indeed be captured by the single
standardised factor, ‘g’.
Initial two-tailed Pearson correlations tested associations of NT-
proBNP with other clinical measures, cognitive outcome and
HADS depression scores. Mean NT-proBNP levels were com-
pared between groups with suspected dementia (MMSE,24), and
between those with suspected clinical depression (HADS-D score
$8) and those without.
In exploratory univariate analyses, mean ‘g’ and HADS
depression scores were compared between the highest and the
lower four quintile NT-proBNP groups. The likelihood of low
cognitive functioning (scoring in the lowest versus intermediate or
NT-proBNP Associations with Cognition/Depression
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highest tertiles of ‘g’) and of suspected clinical depression were
calculated for the highest quintile NT-proBNP as an example of a
group with raised NT-proBNP levels.
Scores on the different cognitive tests were also treated as
individual continuous outcome variables. NT-proBNP was mod-
elled on each of these, ‘g’, and HADS depression, adjusting for
potential confounders in staged and cumulative linear regression
analyses. Confounders were selected on the basis of results from
exploratory univariate analyses and reports in the literature of
confounding or mediating roles in the relationship of NT-proBNP
with cognition or depression. Results from the regression analyses
were presented as b regression coefficients to show the direction
and strength of the associations, signifying the change in cognitive
and depression scores for each unit increase in NT-proBNP.
For cognitive outcome variables, only age and sex were
controlled for in a first model. Estimated pre-morbid cognitive
ability (MHVS) was entered in a second stage, before the addition
of diabetes-related and cardiovascular risk factor variables
(smoking status, blood pressure, BMI, HbA1c, cholesterol and
mode of treatment). MI, angina, stroke and ankle brachial index
(ABI) were then entered, but had not previously been included in
order to avoid over-adjustment. HADS depression scores were
added in a final model in order to determine the potential
independence of NT-proBNP associations with cognition and
depression. The first two modelling steps were also followed for the
HADS depression outcome. In a third step, HbA1c and mode of
treatment were controlled for. Cardiovascular disease variables
were only added into the model in a final step, again in order to
avoid over-adjustment given the role of NT-proBNP as a marker
of cardiovascular disease. Analyses were performed using SPSS for
Windows, version 14.0 (IBM Corporation, New York).
Results
Cohort characteristics and classical risk factors
Characteristics of the ET2DS participants are shown in Table 1.
The study population (n = 1066) has been shown previously to be
largely representative of all people invited to participate in the
study (n= 5454) and therefore of the target population of older
men and women with type 2 diabetes living in the general
population [35]. Mean age was 67.9 years. Mean plasma NT-
proBNP levels were similar in men and women (geometric means
79 pg/ml 63 vs 84 pg/ml 63; p = 0.41 and correlated positively
with age (r = 0.25; p,0.001). Controlling for age and sex, NT-
proBNP was significantly associated with the following variables:
duration of diabetes (r = 0.14; p,0.001), diastolic blood pressure
(r =20.09; p= 0.008), ABI (r =20.14; p,0.001), BMI (r = 0.11;
p,0.001) and cholesterol (r =20.10; p = 0.005), but not with
HbA1c, plasma glucose or systolic blood pressure (p.0.05). Mean
levels differed between individuals with MI, stroke or angina and
those without (p,0.001 respectively), but not between smokers
and non-smokers (p.0.05).
NT-proBNP associations with cognitive performance
After controlling for age and sex, NT-proBNP was weakly but
statistically significantly correlated with decreased performance on
MHVS, Logical Memory, TMT-B, DSC, MR, the general ability
factor ‘g’ and HADS depression. NT-proBNP levels accounted for
,1% of variance in cognitive test scores and ‘g’ (r2 = 0.005 to
0.008), and for 1.7% of depression scores. (r2 = 0.017; Table 2).
NT-proBNP was not significantly different in the small group of
participants with possible dementia (MMSE,24, n = 30) com-
pared with higher scoring individuals (geometric mean 106 pg/ml
63 vs 81 pg/ml 63, p = 0.24). However, the group with possible
clinical depression (HADS depression score $8, n= 78) had lower
mean MMSE scores (geometric means 27.8061.08 vs
28.2861.08, p = 0.052, Cohen’s d=0.24) and higher NT-proBNP
levels (geometric mean 107 pg/ml 63 vs 80 pg/ml 63, p = 0.03,
Cohen’s d=0.28) compared to the non-depressed group.
To further explore whether plasma NT-proBNP could be a
marker of reduced cognitive function irrespective of other possible
markers, we examined differences in cognitive ability across
quintiles of NT-proBNP (geometric cutpoints were 29.70, 59.15,
100.48 and 217.02 pg/ml). An analysis of covariance with
adjustment for age and sex suggested an overall trend across
quintiles (adjusted mean ‘g’ = 0.02, 0.14, 0.13, 20.09 and 20.18
respectively; p= 0.003). Subjects in the highest quintile of NT-
proBNP (n= 199) had lower ‘g’ than those in the remaining four
quintiles (n = 807; adjusted means 20.18 versus 0.05; 95% CI for
difference 20.39, 20.08; p = 0.003). In unadjusted analyses
comparing the highest quintile of NT-proBNP to all other
quintiles, the odds ratios for low cognitive ability (‘g’ in the lowest
tertile) was 2.14 (95% CI: 1.44, 3.18; p,0.001). After adjustment
for age and sex, the association was marginally attenuated to 1.80
(95% CI: 1.20, 2.70; p = 0.005).
For ‘g’ and each of the constituent cognitive tests, multiple
regression analyses were carried out (Table 3). The initial model
controlled for age and sex. Associations with NT-proBNP reached
statistical significance for a number of cognitive tests (Logical
Memory, TMT-B, DSC, MR), and ‘g’. In a second step, pre-
morbid cognitive ability (MHVS) was added into the model. The
associations with TMT-B, DSC, MR, and ‘g’ remained statistically
significant, and for Logical Memory approached significance.
When a range of potential confounding and/or mediating
variables, including conventional cardiovascular risk factors
together with HbA1c and treatment type were added in a third
model, only the association with Logical Memory remained
statistically significant and also survived the further adjustment for
previous cardiovascular disease and HADS depression in a final
step.
NT-proBNP associations with depression
Adjusting for age and sex, HADS depression scores gradually
increased across NT-proBNP quintiles (geometric mean scores
were 2.77, 2.94, 3.19, 3.25 and 3.56 respectively; p = 0.007). The
highest NT-proBNP quintile had higher mean depression scores
compared with the lower four quintiles (95% CI 0.05, 0.28;
p = 0.006). The age- and sex-adjusted odds ratio (OR) for possible
clinical depression, comparing the highest versus the lower four
quintiles, was 2.18 (95% CI 1.28, 3.71; p = 0.004).
Multivariable modelling was repeated for HADS depression.
The age and sex adjusted association reached significance and
survived additional adjustment for pre-morbid cognitive ability, as
well as diabetes-associated variables. The association became non-
significant following the addition of previous cardiovascular
disease into the model (Table 4).
Discussion
This epidemiological study investigated the contribution of NT-
proBNP levels to performance on a large battery of cognitive tests
and symptoms of depression in older people with type 2 diabetes
using one of the largest community-based study populations on
this topic. Cognitive ability, measured by the standardised factor
‘g’, was lower, and depression higher, in patients with raised
plasma NT-proBNP. Participants with peptide levels in the highest
quintile of NT-proBNP distribution were almost two times more
likely to have reduced cognitive ability (lowest tertile of ‘g’) and
NT-proBNP Associations with Cognition/Depression
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were more than two times more likely to have possible clinical
depression following the adjustment for age and sex, compared
with the remaining population, but associations of NT-proBNP
with ‘g’ and depression scores no longer reached statistical
significance when diabetes-related and vascular co-variates were
additionally controlled for.
Although not the main focus of the present investigation, raised
NT-proBNP was also found to be associated with poorer pre-
morbid cognitive ability. This finding could cast doubt over a
causal relationship between cardiac stress (as measured by
natriuretic peptides) and late-life cognitive ability in people with
diabetes, since ‘reverse causation’ and confounding are possible
explanations [43]. Low early life cognitive ability leads to lower
late-life ability, and exposes individuals to poor lifestyle choices,
health problems with associated raised biomarker levels, and
earlier death [44]. However, the reported weak associations
between NT-proBNP and current cognitive ability remained
significant when pre-morbid ability was controlled for.
The association between reduced late-life cognitive ability and
plasma NT-proBNP is consistent with previous studies on
predominantly non-diabetic populations [12–14]. However, pre-
vious studies have predominantly used simple screening instru-
ments, such as the MMSE, to measure cognitive function. Our use
of a general ability factor derived from a number of different
cognitive tests is unique in the literature on NT-proBNP and
cognition. Although the age- and sex-adjusted odds of reduced
cognitive ability for the high NT-proBNP group were comparable
to those reported by Daniels et al. [12], the multivariate
associations between NT-proBNP and cognitive scores were
relatively weak compared with some previous investigations
[13,14]. Peptide levels were also similar in subjects with and
without suspected dementia determined using the MMSE
(MMSE,24) compared with others. This finding is consistent
with previous studies [15,30,31], but may reflect flaws in the use of
the MMSE, designed to screen for dementia, as a measure of
milder forms of cognitive impairment [45].
Table 1. Baseline characteristics of the ET2DS population.
Variable Mean ± SD, median (quartile range) or n (%)
Age (years) 67.964.2
Male sex (%) 547 (51.3)
Duration of diabetes (years) 6 (3–11)
Treatment of diabetes with insulin +/2 tablets 186 (17)
Treatment with tablets alone 679 (64)
Treatment with dietary change alone 200 (19)
HbA1c (%) 7.461.1
Fasting plasma glucose (mmol/L) 7.662.1
Systolic BP (mmHg) 133616
Diastolic BP (mmHg) 6969
Myocardial infarction 150 (14)
Angina 298 (28)
Stroke 62 (6)
ABI 0.9860.21
BMI (kg/m2) 31.465.7
Total cholesterol (mmol/L) 4.360.9
Smoking (current) (%) 153 (14.4)
NT-proBNP (pg/ml) 75 (37–169)
Hospital Anxiety and Depression Questionnaire (HADS): Depression score 3 (1–6)
HADS depression score $8 78 (7.3)
Mini-Mental State Examination ,24/30 (%) 30 (2.9)
Trail-Making Test B 104 (81–138)
Matrix Reasoning 12.865.3
Digit Symbol Coding 49.2614.8
Verbal Fluency Test 36.9612.8
Letter Number Sequencing 9.762.8
Faces 65.867.9
Logical Memory 25.268.2
g 0.0061.00
Mill Hill Vocabulary Scale 30.965.2
Mean 6 SD is given for normally distributed variables.
Median (quartile range) is given for non-normally distributed variables.
doi:10.1371/journal.pone.0044569.t001
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Associations between NT-proBNP and deficits in specific
cognitive domains were also explored. When age and sex were
controlled for, peptide levels were unrelated to performance on
BVFT, Faces or LNS, but were associated with poor performance
on Logical Memory, TMT-B, DSC and MR. Furthermore, these
relatively weak associations (except that for Logical Memory, for
which a trend was observed) remained statistically significant
following adjustment for estimated pre-morbid ability. The finding
of inverse associations between peptide levels and performance on
the TMT-B test of visual attention and the Matrix Reasoning test
of non-verbal reasoning is consistent with investigations in non-
diabetic populations [12,14]. NT-proBNP was unrelated to verbal
fluency (BVFT) both in the present study and in Gunstad et al.
[14]. Associations in Daniels et al. [12] also only reached statistical
significance when analyses were largely unadjusted. NT-proBNP
has not previously been investigated in relation to nonverbal
memory (Faces), speed of information processing (DSC) or
working memory (LNS), of which we found an association only
with speed of processing. It must be noted that since a large
number of analyses were carried out, it is possible that the
statistically significant associations arose through type I error.
Further studies are required to confirm or refute these findings.
For any disease, the identification of biomarkers indicating
increased risk of complications and co-morbidities is vital to allow
identification of high risk individuals. Despite high prevalence of
vascular disease and associated high average NT-proBNP levels in
people with type 2 diabetes [9,10], as well as high prevalences of
cognitive and mood disorders, to our knowledge, this is the first
investigation to focus on the relationship of NT-proBNP with
cognitive function and mood in type 2 diabetes.
The association of natriuretic peptides with late cognitive ability
may well reflect underlying cardiac stress and associated vascular
disease, rather than any direct causal relationship. This is
supported by the attenuation of the relationship between cognitive
ability and NT-proBNP following the adjustment for a range of
cardiovascular risk factors and cardiovascular disease, which
rendered it statistically non-significant. A weak association
between NT-proBNP and the Logical Memory test (which
measures verbal declarative memory through recall of a short
story and is particularly sensitive to progression of type 2 diabetes
[46]) was unique, in that it was not attenuated by the adjustment
for cardiovascular or diabetes-associated variables, or HADS
depression scores. Despite the possibility that the result represents
a type I error, it is an intriguing finding which merits further
investigation.
Raised NT-proBNP was also associated with high depression
scores, supporting previous findings from non-diabetic populations
[19–22]. The relative weakness of the associations is consistent
with one previous report [22], although associations overall tend to
be larger [19–21]. Despite predicting high risk of future vascular
disease and depression, low pre-morbid ability did not confound
the association. Pathways linking depression and NT-proBNP
levels have been suggested previously [19]. We found evidence
Table 2. Age and sex-adjusted two- tailed partial correlations
of NT-proBNP with cognitive and depression scores.
Partial correlation
coefficient p-value
Mill-Hill Vocabulary
Scale
20.07 0.042
Borkowski Verbal
Fluency
,0.01 0.963
Logical Memory 20.08 0.015
Faces 20.05 0.139
ln(Trail-Making-Test-B) 0.08 0.012
Digit Symbol Coding 20.09 0.006
Letter Number
Sequencing
20.05 0.146
Matrix Reasoning 20.08 0.010
g 20.09 0.007
ln(HADS depression) 0.13 ,0.001
doi:10.1371/journal.pone.0044569.t002
Table 3. Multivariate associations between NT-proBNP and cognitive test scores.
MHVS g BVFT LM FACES ln(TMT-B) DSC LNS MR
Model 1a b 20.26 20.09 0.02 20.49 20.31 0.03 20.96 20.10 20.35
95% CI 20.54, 0.01 20.13, –0.03** 20.65, 0.69 20.91, 20.06*20.71, 0.10 0.01, 0.05* 21.71, 20.20** 20.25, 0.04 20.62, 20.08**
Model 2b b 20.05 0.28 20.36 20.20 0.02 20.69 20.04 20.25
95% CI 20.09, 0.00* 20.33, 20.8920.75, 0.04 20.59, 0.19 0.00, 0.04* 21.38, 0.00* 20.18, 0.90 20.50, 20.01*
Model 3c b 20.04 0.38 20.48 20.15 0.02 20.26 20.04 20.23
95% CI 20.08, 0.01 20.26, 1.01 20.89, 20.07*20.56, 0.26 0.00, 0.04 20.98, 0.46 20.17, 0.10 20.48, 0.02
Model 4d b 20.02 0.18 20.57 20.01 0.02 0.19 20.01 20.15
95% CI 20.07, 0.03 20.52, 0.87 21.02, 20.11*20.46, 0.44 20.01, 0.04 20.60, 0.98 20.16, 0.15 20.43, 0.13
Model 5e b 20.02 0.16 20.56 20.03 0.01 0.26 0.01 20.14
95% CI 20.06, 0.03 20.56, 0.88 21.03, 20.08*20.50, 0.44 20.01, 0.04 20.54, 1.07 20.15, 0.16 20.42, 0.15
The b scores are regression coefficients.
aadjusted for age and sex.
badjusted for +MHVS.
cadjusted for + smoking status, blood pressure, BMI, HbA1c, cholesterol, mode of treatment.
dadjusted for + MI, angina, stroke, ABI.
eadjusted for + ln(HADS depression).
*significant at 0.05 level.
**significant at 0.01 level.
doi:10.1371/journal.pone.0044569.t003
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against this, as the association became non-significant when
previous cardiovascular disease was controlled for. Depression is
associated with a harmful lifestyle and subsequent endothelial
damage, and also accelerates the progression of cardiac illness
through effects on the hypothalamic-pituitary adrenal (HPA) axis,
increasing the risk of heart failure [47]. Conversely, heart failure
and other chronic illness initiate symptoms of depression,
including hypersomnia, fatigue and loss of energy [48], constructs
included in the HADS questionnaire.
Overall, the clinical relevance of natriuretic peptides as
biomarkers for poor cognitive function and depression is unclear.
Despite a relatively weak multivariate association, individuals in
the highest NT-proBNP quintile were substantially more likely to
have reduced cognitive ability and depression compared with the
remaining population. NT-proBNP may function as a biomarker
of subclinical cerebrovascular disease particularly in individuals
who experience cardiac stress. This extends its well-established
role as a predictor of cardiovascular and cerebrovascular events
[49]. Mirroring a greater ability of natriuretic peptides compared
with other biomarkers, such as c-reactive protein (CRP), to predict
these outcomes [50], the association of NT-proBNP with cognitive
function in the present study was also stronger than that of CRP
with cognitive function in a previous analysis [35].
A strength of the current study was the ability to adjust for a
wide variety of variables, both those which are commonly
controlled for (e.g., age), and those which may be confounding
or mediating factors underlying the relationship between NT-
proBNP and cognitive ability (e.g., vascular risk factors; cardio-
vascular disease). Due to the large size of the study, results are
more robust than those of previous investigations carried out on
smaller scales [15–17] and the analysis had high power to detect
even weak associations, although admittedly, the clinical relevance
of such associations is debatable. The latter was reflected in the
conservative interpretation of statistically significant results. The
cross-sectional nature of the study and the resulting unclear
direction of the reported associations is a weakness of the study,
although this was partly offset by our adjustment for pre-morbid
cognitive ability. The MHVS as a measure of pre-morbid ability is
advantageous over the often used level of education, which is
subject to self-report bias.
In conclusion, we found some evidence for NT-proBNP as a
biomarker of low cognitive ability and depression in elderly people
with type 2 diabetes, although the associations were relatively
weak and were largely explained by previous cardiovascular
disease. The value of NT-proBNP measurement over and above
the assessment of traditional markers of cognitive dysfunction and
depression remains unclear, and further studies on its relationship
with these disorders are needed. Analysis of the second wave of
data of the prospective ET2DS will provide an ideal opportunity
to investigate the associations of natriuretic peptide levels with risk
of subsequent cognitive decline and the development of depres-
sion.
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